Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
Clinical trial NCT02292446 · COMPLETED
Trial details
- NCT number
- NCT02292446
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-21
- Primary completion
- 2017-12-29
- Enrollment
- 161
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.